Set, Ready, Afford: China Rushes To Access Innovation Amid New Drug Dash
2018 is set to break the record for new drug approvals in China, which have included some immuno-oncology and powerful antiviral therapies. Providing access to these high-priced medicines to more patients in the populous country was high on the minds of several multinationals during a recent conference in Shanghai.
You may also be interested in...
From AI to IPOs, from access models to mobile payments, China’s biopharma sector increasingly became a global leader in biotech financing and digital health innovation in 2018. Here is Scrip's pick of eight key events that captured the major developments in China’s dynamic, highly fluid biopharma commercial scene throughout the year.
Top executives from three high-flying Chinese biotechs, all of which have gone public on Nasdaq and in Hong Kong, offered lessons learned and looked forward to what’s ahead in a panel session at the recent JPM conference.
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?